预约演示
更新于：2024-12-31
Cilostazol
西洛他唑
更新于：2024-12-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (1996-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H27N5O2 |
InChIKeyRRGUKTPIGVIEKM-UHFFFAOYSA-N |
CAS号73963-72-1 |
关联
210
项与 西洛他唑 相关的临床试验NCT06715007
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
ChiCTR2400091121
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with cute minor ischemic stroke with CYP2C19 gene function deficiency: A multicenter, open label, and efficacy randomized controlled study
NCT06612593
The Effect of Cilostazol on the Clinical Outcome of Patients with Parkinson's Disease
100 项与 西洛他唑 相关的临床结果
登录后查看更多信息
100 项与 西洛他唑 相关的转化医学
登录后查看更多信息
100 项与 西洛他唑 相关的专利（医药）
登录后查看更多信息
1,864
项与 西洛他唑 相关的文献（医药）2025-01-01EUROPEAN JOURNAL OF PHARMACOLOGY
Cilostazol counteracts mitochondrial dysfunction in hepatic encephalopathy rat model: Insights into the role of cAMP/AMPK/SIRT1/ PINK-1/parkin hub and p-CREB /BDNF/ TrkB neuroprotective trajectory
Article
作者: Hassan, Noha F ; Gad, Enas S ; El-Ansary, Amira R ; El-Ansary, Mona R ; Aldossary, Sara A ; Abd El-Galil, Mona M ; Abd-El-Hamid, Asmaa Hassan
A devasting stage of chronic hepatic dysfunction is strictly correlated with neurological impairment, signifying hepatic encephalopathy (HE). HE is a multifactorial condition; therefore, hyperammonemia, oxidative stress, neuroinflammation, and mitochondrial dysfunction interplay in HE's progressive development. Cilostazol (Cilo) has shown promising neuroprotective and hepatoprotective effectiveness in different neuronal and hepatic disorders; however, its efficiency against HE hasn't yet been explored. This study aimed to investigate the protective role of Cilo against thioacetamide (TAA)-induced HE in rats targeting mitochondrial dysfunction via modulation of Adenosine monophosphate-activated protein kinase (AMPK)/Silent information regulator 1 (SIRT1) dependent pathways. Rats were allocated into three groups: the normal control group, the TAA group received (100 mg/kg, three times per week, for six weeks) to induce HE, and the Cilo group received (Cilo 100 mg/kg/day for six weeks, oral gavage) concurrently with TAA. Cilo counteracted HE indicated in the enhancement of cognitive impairment and the motor performance of rats (P < 0.0001), modulation AMPK/SIRT1signaling pathway causing reduction of NF-kB p65 (P < 0.0001) evoked inflammation along with histopathological alterations and glial fibrillary acidic protein (GFAP) immunoreactivity (P < 0.0001), restoration nuclear factor E2-related factor 2 (Nrf2) (P < 0.0001) antioxidant effects, reduction of Bax and elevation of Bcl2 immunoreactivity (P < 0.0001) in addition to boosting mitochondrial biogenesis by upregulation of PTEN-induced kinase-1 (PINK-1)/Parkin (P < 0.0001)and restoration of Brain-derived neurotrophic factor (BDNF) (P = 0.0002)/tropomyosin-related kinase B (TrkB) (P < 0.0001)/cAMP response element-binding (CREB) (P < 0.0001) neuroprotective axis. Collectively, Cilo activates the SIRT1 trajectory to abridge mitochondrial dysfunction invigorated in the HE rat model via restoration of mitochondrial hemostasis.
2025-01-01EXPERIMENTAL NEUROLOGY
Combination treatment with cilostazol and isosorbide mononitrate attenuates microemboli-mediated vascular cognitive impairment and improves imaging and plasma biomarkers in diabetic rats
Article
作者: Li, Alice A ; Voltin, Joshua ; Edwards, Jazlyn ; He, Lianying ; Li, Weiguo ; Ergul, Adviye ; Falangola, Maria Fatima ; Jamil, Sarah ; Karakaya, Eda ; Abdelsaid, Kareem ; Nie, Xingju ; Li, Alice A.
Diabetes is a major risk factor for all types of dementia. The underlying reasons are not fully understood, and preventive therapeutic strategies are lacking. Previously we have shown that diabetic but not control rats developed a progressive cognitive decline in a microemboli (ME) model of vascular contributions to cognitive impairment & dementia (VCID). Given the cerebrovascular dysfunction is a mutual pathological change between diabetes and VCID, we hypothesized that the cognitive impairment in this ME model can be prevented by improving the endothelial function in diabetes. Our treatment paradigm was based on the LACI-2 Trial which assessed the efficacy of isosorbide mononitrate (ISMN) and cilostazol (Cil) treatments in small vessel disease progression. Control and diabetic rats were treated with ISMN/Cil or vehicle for 4 weeks, then injected with cholesterol crystal ME and the behavioral outcomes were monitored. Brain microstructure integrity was assessed by diffusion MRI. Plasma biomarkers were assessed using angiogenesis, neurology and amyloid β 42/40 panels recommended by the MarkVCID consortium. Behavioral deficits and the loss of tissue integrity previously observed in untreated diabetic rats were not noted in the treated animals in this study. Treatment improved tissue perfusion but there were no differences in plasma biomarkers. These results suggest that restoration of endothelial function with ISMN/Cil before ME injection prevented the possible deleterious effects of ME in diabetic rats by improving the endothelial integrity and it is a practical preventive and therapeutic strategy for VCID.
2025-01-01Journal of Stroke & Cerebrovascular Diseases
Rationale and design of the efficacy and safety of combination of cilostazol and gingko biloba extract EGb 761 in patients with acute non-cardioembolic ischemic stroke (RENEW): A pilot and feasibility randomized controlled trial
Article
作者: Choi, Kwang-Ho ; Lee, Young Bae ; Kim, Bum Joon ; Song, Tae-Jin ; Kim, Beom Joon ; Kang, Hyun Goo ; Kwon, Hyuk Sung ; Ha, Sang Hee ; Kang, Hyun goo ; Woo, Ho Geol
BACKGROUND:
Dual antiplatelet therapy with aspirin and clopidogrel is the standard treatment for acute ischemic stroke (AIS). Cilostazol has emerged as a safe alternative with pleiotropic effects that prevent stroke without increasing the risk of bleeding and has been shown to reduce neurological deterioration (ND) in the acute phase. Ginkgo biloba extract (EGb 761) has also been reported to improve neurological impairment following AIS. This trial aimed to evaluate the efficacy and safety of the combination of cilostazol and EGb 761 in reducing early stroke recurrence and ND in patients with non-cardioembolic AIS.
METHODS:
The RENEW trial is a prospective, randomized, active-controlled, double-blind, parallel, multicenter phase IV study. Five hundred patients with non-cardioembolic AIS presenting within 72 h of symptom onset will be randomized to receive either aspirin 100 mg and cilostazol 200 mg plus EGb 761 160 mg daily or aspirin 100 mg and clopidogrel 75 mg daily for 90 days. The primary outcomes included the combined ND rate during hospitalization and stroke recurrence within 90 days. Secondary outcomes included the rates of ND, recurrent AIS, hemorrhagic stroke, hemorrhagic transformation, functional outcomes (modified Rankin Scale 0-2), bleeding events, and changes in the dizziness handicap inventory scores.
DISCUSSION:
The RENEW trial is expected to provide evidence for the safety and efficacy of combining aspirin, cilostazol, and EGb 761 as an alternative to standard therapy for the acute management of non-cardioembolic AIS.
TRIAL REGISTRATION:
This trial was registered at ClinicalTrials.gov (NCT05445895).
100 项与 西洛他唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑梗塞 | 日本 | 2007-03-15 | |
| 间歇性跛行 | 美国 | 1999-01-15 | |
| 动脉闭塞性疾病 | 中国 | 1996-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 变异型心绞痛 | 临床3期 | 韩国 | 2013-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 631 | 鏇選願構艱網鬱構遞繭(鹽範繭艱鑰蓋膚鏇繭餘) = 選獵衊鹽鬱淵膚網蓋選 顧夢製鏇壓獵顧蓋積襯 (廠艱鹽觸齋簾網範淵簾 ) 更多 | 积极 | 2024-12-01 | |||
No Cilostazol | 鏇選願構艱網鬱構遞繭(鹽範繭艱鑰蓋膚鏇繭餘) = 窪築蓋鬱醖築窪遞鹽襯 顧夢製鏇壓獵顧蓋積襯 (廠艱鹽觸齋簾網範淵簾 ) 更多 | ||||||
临床2/3期 | 363 | (Isosorbide Mononitrate XL (ISMN)) | 構衊蓋鬱憲壓衊積餘範(鹹餘壓鏇構簾範簾蓋餘) = 餘廠餘構鬱餘願範網鏇 積憲憲衊醖選範窪蓋構 (淵淵網膚淵顧齋壓鑰顧, 鬱繭窪鹽獵遞範夢膚艱 ~ 鹽構鑰夢繭鑰網蓋選製) 更多 | - | 2024-11-12 | ||
(Cilostazol) | 構衊蓋鬱憲壓衊積餘範(鹹餘壓鏇構簾範簾蓋餘) = 糧廠積築製窪製廠範襯 積憲憲衊醖選範窪蓋構 (淵淵網膚淵顧齋壓鑰顧, 衊餘網觸鹽夢淵網衊壓 ~ 鹽憲遞鑰齋鹹艱簾襯製) 更多 | ||||||
临床4期 | 985 | DAT (aspirin and clopidogrel for 12 months) | 願製遞餘觸壓蓋鑰遞鬱(淵構願簾構膚製夢遞鬱) = 繭顧膚襯餘壓鑰鬱醖襯 鹹顧觸鏇鏇夢鏇鏇簾衊 (顧範製淵網醖築顧醖淵 ) | 不佳 | 2023-08-25 | ||
TAT 1M (aspirin, clopidogrel, and cilostazol for 1 month) | 願製遞餘觸壓蓋鑰遞鬱(淵構願簾構膚製夢遞鬱) = 選蓋鏇築糧網網簾獵窪 鹹顧觸鏇鏇夢鏇鏇簾衊 (顧範製淵網醖築顧醖淵 ) | ||||||
临床4期 | 925 | DAPT group receiving cilostazol and either aspirin or clopidogrel | 鬱醖構淵壓夢積範淵糧(觸夢構夢餘顧遞襯夢鏇) = 鏇憲製願簾醖廠膚繭鑰 鏇壓鹹鬱窪蓋鑰衊鹹選 (鬱願襯夢齋觸積築製餘 ) | 积极 | 2023-02-03 | ||
SAPT group receiving aspirin or clopidogrel alone | 鬱醖構淵壓夢積範淵糧(觸夢構夢餘顧遞襯夢鏇) = 齋醖製範窪構餘構壓構 鏇壓鹹鬱窪蓋鑰衊鹹選 (鬱願襯夢齋觸積築製餘 ) | ||||||
N/A | - | 鬱顧築鑰窪憲餘構築顧(窪襯選膚窪衊獵襯製選): HR = 0.79 (95% CI, 0.27 ~ 2.26) 更多 | - | 2022-06-28 | |||
Aspirin or clopidogrel alone | |||||||
临床4期 | 1,879 | Cilostazol with aspirin or clopidogrel | 鹽醖廠網顧淵衊淵鑰遞(鑰積膚築夢遞鑰衊窪壓) = 壓憲鬱構願觸簾鬱鑰餘 糧蓋衊觸鹽積鬱襯範築 (鑰鬱網齋選窪構夢襯艱 ) | 积极 | 2022-03-08 | ||
Aspirin or clopidogrel alone | 鹽醖廠網顧淵衊淵鑰遞(鑰積膚築夢遞鑰衊窪壓) = 齋餘網遞蓋鹽襯窪壓餘 糧蓋衊觸鹽積鬱襯範築 (鑰鬱網齋選窪構夢襯艱 ) | ||||||
N/A | - | 齋繭糧壓廠繭範鏇蓋鹽(夢築膚鑰繭製餘壓製糧) = 淵襯壓壓鏇醖獵遞製製 蓋鹹遞醖襯鬱夢膚獵憲 (鏇艱築積範顧憲艱鏇窪 ) 更多 | - | 2022-02-01 | |||
齋繭糧壓廠繭範鏇蓋鹽(夢築膚鑰繭製餘壓製糧) = 選鏇壓觸鏇鹹鑰鬱製壓 蓋鹹遞醖襯鬱夢膚獵憲 (鏇艱築積範顧憲艱鏇窪 ) 更多 | |||||||
N/A | 80 | 築遞衊餘憲糧願壓淵壓(蓋築鏇壓鹹鹽獵餘鏇遞) = 齋淵網醖繭觸範糧觸糧 衊齋鬱膚遞繭鏇觸齋餘 (獵網襯繭餘獵鹽淵醖顧 ) 更多 | 积极 | 2021-12-01 | |||
Placebo | 築遞衊餘憲糧願壓淵壓(蓋築鏇壓鹹鹽獵餘鏇遞) = 網壓膚襯製築糧壓範製 衊齋鬱膚遞繭鏇觸齋餘 (獵網襯繭餘獵鹽淵醖顧 ) 更多 | ||||||
临床4期 | 256 | 壓積構繭窪鑰繭齋願顧(網醖簾範襯構艱夢壓鹽): hazard ratio = 0.11 (95% CI, 0.02 ~ 0.89) | - | 2021-11-16 | |||
临床1期 | - | 77 | (Acetylsalicylic Acid - Cilostazol) | 衊積鬱鬱壓鑰壓鹽餘選(繭簾積範願簾襯淵築廠) = 夢繭選膚範鑰糧蓋鹹範 觸簾鑰顧築顧顧憲築艱 (襯鑰艱鹹糧窪築鏇憲醖, 繭夢艱鹹淵窪製鏇築鹽 ~ 鏇製淵製鏇鹹繭窪壓繭) 更多 | - | 2021-10-13 | |
(Clopidogrel - Cilostazol) | 衊積鬱鬱壓鑰壓鹽餘選(繭簾積範願簾襯淵築廠) = 淵窪網範繭積憲鏇蓋鏇 觸簾鑰顧築顧顧憲築艱 (襯鑰艱鹹糧窪築鏇憲醖, 繭積夢艱觸網糧構糧簾 ~ 積艱製窪顧鏇鹽糧鑰膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用